Literature DB >> 26614366

Pathologic Classification of Neuroendocrine Neoplasms.

David S Klimstra1.   

Abstract

The pathologic classification of neuroendocrine neoplasms has evolved over the past decades, as new understanding of the biological behavior, histologic characteristics, and genetic features have emerged. Nonetheless, many aspects of the classification systems remain confusing or controversial. Despite these difficulties, much progress has been made in determining the features predicting behavior. Genetic findings have helped establish relationships among different types of neuroendocrine neoplasms and revealed potential therapeutic targets. This review summarizes the current approach to the diagnosis, classification, grading, and therapeutic stratification of neuroendocrine neoplasms, with a focus on those arising in the lung and thymus, pancreas, and intestines.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Intestines; Lung; Neuroendocrine; Pancreas; Pathological classification; Thymus

Mesh:

Substances:

Year:  2015        PMID: 26614366     DOI: 10.1016/j.hoc.2015.08.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  21 in total

Review 1.  Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications.

Authors:  Günter Klöppel
Journal:  Visc Med       Date:  2017-10-16

Review 2.  Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms.

Authors:  Georgios Kyriakopoulos; Vasiliki Mavroeidi; Eleftherios Chatzellis; Gregory A Kaltsas; Krystallenia I Alexandraki
Journal:  Ann Transl Med       Date:  2018-06

3.  Reassessing the grade of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  David S Klimstra
Journal:  Endocrine       Date:  2016-05-05       Impact factor: 3.633

Review 4.  Carcinoid-syndrome: recent advances, current status and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-02       Impact factor: 3.243

Review 5.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

6.  Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.

Authors:  Xin Wang; Yuanliang Li; Jianghui Duan; Yingying Chen; Bing Yuan; Zhirong Qi; Huangying Tan
Journal:  Oncologist       Date:  2018-11-09

Review 7.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

8.  Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience.

Authors:  Javier A Cienfuegos; Joseba Salguero; Jorge M Núñez-Córdoba; Miguel Ruiz-Canela; Alberto Benito; Sira Ocaña; Gabriel Zozaya; Pablo Martí-Cruchaga; Fernando Pardo; José Luis Hernández-Lizoáin; Fernando Rotellar
Journal:  Surg Endosc       Date:  2017-01-26       Impact factor: 4.584

Review 9.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

10.  Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.

Authors:  Giuseppe Pelosi; Fabrizio Bianchi; Elisa Dama; Michele Simbolo; Andrea Mafficini; Angelica Sonzogni; Sara Pilotto; Sergio Harari; Mauro Papotti; Marco Volante; Gabriella Fontanini; Luca Mastracci; Adriana Albini; Emilio Bria; Fiorella Calabrese; Aldo Scarpa
Journal:  Virchows Arch       Date:  2018-02-01       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.